Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) Malhotra A, Grunstein RR, Fietze I, et al
Suicidality: under active investigation Regulatory bodies, including the European Medicines Agency, have been reviewing a potential association between GLP-1 drugs and suicidal ideation
Depression is a prevalent mood disorder and a significant health concern that often co-occurs with other diseases including metabolic disorders like T2DM and obesity [23]
On average, people taking semaglutide lost 14.9% of their body weight , compared to a 2.4% body weight loss in the placebo group
Novo Nordisk has filed almost 120 lawsuits across 34 states against companies marketing or selling knockoff GLP-1 drugs, winning 28 final judgments so far, according to Novo Nordisk